Неврология, нейропсихиатрия, психосоматика
Т. 10, Вып. 4, С. 101-110
Аннотация:
This review provides information on prospects for using the antidepressant agomelatine in neurological practice. The drug has a unique receptor profile, being a melatonin receptor type 1 and 2 agonist and a serotonin receptor subtype 2C antagonist. Due to this and in addition to antidepressant action, the drug has a number of other effects, such as analgesic, anti-apathetic, anti-asthenic, procognitive, anxiolytic, and sleep-normalizing ones, which are of great importance in the treatment of neurological diseases. There are clinical and experimental data that prove the high efficiency and safety of agomelatin in the follow-up of patients with post-stroke depression, Parkinson's disease, Alzheimer's disease, Pick's disease, Huntington's disease, chronic fatigue syndrome, and pain syndromes. © 2018 Ima-Press Publishing House. All Rights Reserved.
Романов Д. В. Дмитрий Владимирович 1980-
Волель Б. А. Беатриса Альбертовна 1976-
Петелин Д. С. Дмитрий Сергеевич 1990-
Romanov D. V. Dmitrij Vladimirovich 1980-
Volel` B. A. Beatrisa Al`bertovna 1976-
Petelin D. S. Dmitrij Sergeevich 1990-
Approaches to therapy for depressions in neurology: Prospects for the use of agomelatine
Текст визуальный непосредственный
Неврология, нейропсихиатрия, психосоматика
ИМА-Пресс
Т. 10, Вып. 4 С. 101-110
2018
Статья
Agomelatine (valdoxan) Anxiety Apathy Asthenia Cognitive impairment Depression Insomnia Neurology Pain
This review provides information on prospects for using the antidepressant agomelatine in neurological practice. The drug has a unique receptor profile, being a melatonin receptor type 1 and 2 agonist and a serotonin receptor subtype 2C antagonist. Due to this and in addition to antidepressant action, the drug has a number of other effects, such as analgesic, anti-apathetic, anti-asthenic, procognitive, anxiolytic, and sleep-normalizing ones, which are of great importance in the treatment of neurological diseases. There are clinical and experimental data that prove the high efficiency and safety of agomelatin in the follow-up of patients with post-stroke depression, Parkinson's disease, Alzheimer's disease, Pick's disease, Huntington's disease, chronic fatigue syndrome, and pain syndromes. © 2018 Ima-Press Publishing House. All Rights Reserved.